FUNDING
Karyopharm Announces $165 Million Private Placement
Karyopharm expects to use the proceeds from the private placement, together with its existing cash, cash equivalents and investments, for the advancement of the Company's clinical development programs with selinexor and eltanexor as well as for working capital and other general corporate purposes.
Acer Therapeutics Announces $1.5M Private Placement
The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.
Novigenix Announces First Closing of Its $20M Series B
The proceeds will be utilized to fast track the clinical validation of Novigenix´s second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays.
Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called Chimeric Antigen Receptor (CAR) macrophages. Depending on results, this grant funding could increase up to $1 million.
GlycoNet and Partners Invest $6.5 Million in Carbohydrate Research with One Health Focus
GlycoNet notes the funding will support research critical to improving the health of humans, animals, and the environment.
Enzyre closes Series A financing round of EUR 12M
Enzyre notes the funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities.